Altavilla G et al. - A case of a male Italian smoker with an adeno-carcinoma of the lung whose lung cancer and brain metastases have both responded to erlotinib.
To date, there have been only 5 reported cases of responses to brain metastases in NSCLC pts receiving erlotinib
3 pts harboured L858R mutation while in 2 pts EGFR status was not assessed
The findings presented in this study is of a patient with metastatic NSCLC , carried EGFR mutation L858R
This pt’s response to erlotinib therapy is in agreement with the 3 reported cases
Thus erlotinib could be an appropriate option in NSCLC pts, L858R mutation, and CNS metastases for whom systemic chemotherapy might have little benefit
See all
